NDUFAB1 and allergic disease: Through this ‘hard science’ approach, by leveraging known anti-allergic drug target information, we were able to computationally derive the unique and common compounds, targets, and pathways of ACP therapy for allergic diseases, thereby providing a robust framework to analyze the similarities and differences in the potential compounds and mechanisms of ACP compared to anti-allergic drugs.